Want to see HK:9877 full AI Analyst Report?
9877 Stock Chart & Stats
HK$7.40
-HK$0.14(-1.84%)
At close: 4:00 PM EDT
HK$7.40
-HK$0.14(-1.84%)
Day’s Range― - ―
52-Week RangeHK$6.00 - HK$11.98
Previous CloseN/A
Volume5.82M
Average Volume (3M)37.78K
Market Cap
HK$3.83B
Enterprise ValueHK$2.63B
Total Cash (Recent Filing)HK$414.54M
Total Debt (Recent Filing)HK$39.68M
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Mar 31, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding310,306,200
10 Day Avg. Volume80,240
30 Day Avg. Volume37,785
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)4.22
Price to Sales (P/S)37.79
P/FCF Ratio-41.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.09
Revenue Forecast (FY)HK$261.02M
Bulls Say, Bears Say
Bulls Say
Revenue Ramp And Gross MarginThe sharp revenue ramp indicates that Jenscare has moved beyond development toward commercial adoption of its structural heart products. A gross margin near 75% also suggests attractive product economics, providing potential operating leverage as sales expand and the installed commercial base grows.
Low Financial LeverageVery modest leverage gives Jenscare greater balance-sheet resilience while it scales commercialization. Limited debt reduces interest and refinancing pressure, preserving flexibility to invest in products, clinical adoption, and market expansion even though the company has not yet reached profitability.
Improving Cash BurnAlthough cash generation remains negative, the reduction in operating cash outflow versus prior years signals progress in controlling the cash cost of building the business. If sustained alongside revenue growth, improved burn could extend financial flexibility and reduce the pace of future funding requirements.
Bears Say
Deep Net LossesThe scale of current losses relative to the 2025 revenue base shows that Jenscare has not established earnings power yet. Persistent losses can consume accumulated capital, delay self-funding, and make the company dependent on continued commercialization progress before shareholders see sustainable profitability.
Negative Free Cash FlowNegative operating and free cash flow means the business is still consuming cash to operate and invest rather than funding itself internally. Continued cash deficits create ongoing financing needs and leave execution sensitive to the pace at which product sales and gross profit can cover operating commitments.
Operating Costs Exceed Revenue BaseThe gap between operating expenses and the current revenue base indicates that Jenscare’s cost structure remains substantially ahead of commercialization scale. Strong gross margin alone cannot offset that gap today, so the company must grow revenue materially or manage expenses effectively to approach break-even.
Jenscare Scientific Co. Ltd. Class H News
9877 FAQ
What was Jenscare Scientific Co. Ltd. Class H’s price range in the past 12 months?
Jenscare Scientific Co. Ltd. Class H lowest stock price was HK$6.00 and its highest was HK$11.98 in the past 12 months.
What is Jenscare Scientific Co. Ltd. Class H’s market cap?
Jenscare Scientific Co. Ltd. Class H’s market cap is HK$3.83B.
When is Jenscare Scientific Co. Ltd. Class H’s upcoming earnings report date?
Jenscare Scientific Co. Ltd. Class H’s upcoming earnings report date is Mar 31, 2027 which is in 164 days.
How were Jenscare Scientific Co. Ltd. Class H’s earnings last quarter?
Jenscare Scientific Co. Ltd. Class H released its earnings results on Aug 31, 2026. The company reported -HK$0.13 earnings per share for the quarter.
Is Jenscare Scientific Co. Ltd. Class H overvalued?
According to Wall Street analysts Jenscare Scientific Co. Ltd. Class H’s price is currently Overvalued.
Does Jenscare Scientific Co. Ltd. Class H pay dividends?
Jenscare Scientific Co. Ltd. Class H does not currently pay dividends.
What is Jenscare Scientific Co. Ltd. Class H’s EPS estimate?
Jenscare Scientific Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jenscare Scientific Co. Ltd. Class H have?
Jenscare Scientific Co. Ltd. Class H has 310,306,200 shares outstanding.
What happened to Jenscare Scientific Co. Ltd. Class H’s price movement after its last earnings report?
Jenscare Scientific Co. Ltd. Class H reported an EPS of -HK$0.13 in its last earnings report. Following the earnings report the stock price went up 0.277%.
Which hedge fund is a major shareholder of Jenscare Scientific Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:9877
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jenscare Scientific Co. Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.61%
12-Months-Change
Fundamentals
Return on Equity
-19.31%
Trailing 12-Months
Asset Growth
-8.25%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Jenscare Scientific Co. Ltd. Class H
Jenscare Scientific Co., Ltd. operates as a medical technology enterprise dedicated to advancing interventional therapies for structural heart conditions within the People's Republic of China. Among its pipeline, the company features LuX-Valve, an investigational transcatheter tricuspid valve replacement (TTVR) system designed for patients suffering from severe tricuspid regurgitation who face elevated surgical risks. Additionally, Ken-Valve represents another key product candidate, a transcatheter aortic valve replacement (TAVR) aimed at addressing severe aortic regurgitation, often co-occurring with aortic stenosis. The applications of Jenscare's portfolio extend to a range of structural cardiac maladies, including disorders of the tricuspid, aortic, and mitral valves, as well as heart failure. Founded in 2011, the company maintains its principal place of business in Ningbo, People's Republic of China.
Technical Analysis
Peijia Medical Ltd.
―
LifeTech Scientific Corporation
―
Shanghai Kindly Medical Instruments Co., Ltd. Class H
―
AK Medical Holdings Ltd.
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―